NeuroDerm announces start of a pharmacokinetic, head-to-head comparison study of ND0612H and DuodopaNeuroDerm, Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has started a pharmacokinetic (PK) clinical study to determine the dosing of the company's lead product candidate, ND0612H, a subcutaneously administered liquid formulation of levodopa (LD) and carbidopa (CD), for the treatment of advanced Parkinson's Disease.11 June 2015

There's finally something awesome to do with Google GlassGoogle Glass was a failure. At least, according to most people. But not for one specific group: people with Parkinson's. They've been experimenting with new software for Glass and say that it improves the quality of their lives.10 June 2015